Video TCT 2017 PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis Presenter: Patrick W. Serruys October 31, 2017 REGISTER for free or LOG IN to view this content TCT 2017 We Recommend